Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078649 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Debiopharm International.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01078649 is a Phase 1 study that has completed, run by Debiopharm International. The registered enrollment target is 51 participants.
The verdict
NCT01078649, a Phase 1 study, has completed, sponsored by Debiopharm International.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans. This study is also designed to measure how much Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143 (AT-406) interacts with proteins related to cancer that the drug is targeted to affect (pharmacodynamics).
Interventions
- DRUG Debio 1143 (AT-406)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2010-03-29 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078649
The ClinicalTrials.gov registry entry for NCT01078649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Debio 1143 (AT-406) is the first listed.
NCT01078649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078649 about?
NCT01078649 is a clinical study titled "Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas". The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans. This study is also designed to measure how much Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143 (AT-406) interacts with proteins...
What is the current status of trial NCT01078649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2010-03-29. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01078649?
The interventions under investigation include: Debio 1143 (AT-406) (DRUG).
Who is sponsoring clinical trial NCT01078649?
This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.